Replies to post #21270 on Ocata Therapeutics Inc fka OCAT

[rocky301]

elk,


If you haven't already read this link I posted a while back please take the time, at least I feel it is very related in many ways to where and what we are doing and the possibilities of the route we are taking with the Orphan Drug scenario.
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=43742448

The partner I allude to would be in the form of what is said below which is taken from above link.

"The fact remains that it is still the biotech and small pharmaceutical companies that are investing in the early stages of orphan drug development. Big pharmaceutical companies enter the picture once the drug has passed the discovery stage and a significant part of development, too.
Most often, big companies choose to acquire or collaborate with biotech companies rather than start a new drug development program targeting an orphan disease. This strategy has been a boon for biotech companies, which often struggle with inadequate funding. It has also worked well for the venture capital community, as it provides a good exit strategy."

elk, when or if the Orphan strategy works out for ACTC I firmly believe many eyes(pun intended) will be focused on ACTC and the enormous possibilities when they zero in on the AMD indication which has many $$$$$$$$$ attached to success. This would be the prime time for a major Pharma partner or buyout to take the product through commercial stages, imo.

CHA has the resources and potential to benefit ACTC. IMO, I don't think with 33% ownership it will take us to the promised land but feel the partnership is no doubt worthy and look for some developments in the future.